Publications by authors named "Maria R Migliorino"

Claim this Profile
P
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with -positive non-small cell lung cancer.
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Maria Rita Migliorino

Future Sci OA· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.
Floriana Morgillo, Ester Del Signore, Emilio Bria, Filippo de Marinis, Fortunato Ciardiello, Maria Rita Migliorino

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.
Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri

Curr Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
Marina C Garassino, Julien Mazieres, Martin Reck, Christos Chouaid, Helge Bischoff, Maria R Migliorino

J Thorac Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, Tony Mok, Fabrice Barlesi, Maria Rita Migliorino

J Thorac Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Paolo Bironzo, Laura Melocchi, Valentina Monica, Dario Trebeschi, Fausto Barbieri, Maria Rita Migliorino

Pathologica· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients.
Umberto Malapelle, Sara Pilotto, Maria Lucia Reale, Francesco Passiglia, Pasquale Pisapia, Maria Rita Migliorino

Crit Rev Oncol Hematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Maria Rita Migliorino

J Hematol Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, Maximilian J Hochmair, Seung Hyeun Lee, Maria R Migliorino

Lung Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Sergio Bracarda, Massimo Di Maio, Maria R Migliorino

Eur J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Alessio Cortellini, Katia Cannita, Marcello Tiseo, Diego L Cortinovis, Joachim G J V Aerts, Maria R Migliorino

Eur J Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Maria R Migliorino

J Immunother Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Alessio Cortellini, Massimo Di Maio, Olga Nigro, Alessandro Leonetti, Diego L Cortinovis, Maria R Migliorino

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Jean Paty, Rickard Sandin, Arlene Reisman, Yi-Long Wu, Maria Rita Migliorino

Future Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Alessio Cortellini, Andrea De Giglio, Katia Cannita, Diego L Cortinovis, Robin Cornelissen, Maria Rita Migliorino

Thorac Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Tony S Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Maria Rita Migliorino

Drugs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Filippo de Marinis, Konstantin K Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Maria Rita Migliorino

Lung Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Target therapies in translocated ALK lung cancer: treatment management in oncology center of Lazio.].
Serena Ricciardi, Fabiana Cecere, Mario Rosario D'Andrea, Ettore D'Argento, Jonathan Alain Gelibter, Maria Rita Migliorino

Recenti Prog Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, Federico Cappuzzo, Joachim G J V Aerts, Maria R Migliorino

Cancer Immunol Immunother· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Alessio Cortellini, Alex Friedlaender, Giuseppe L Banna, Giampiero Porzio, Melissa Bersanelli, Maria R Migliorino

Clin Lung Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, Emilio Bria, Giuseppe L Banna, Maria R Migliorino

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni, Maria Rita Migliorino

Eur J Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
Alessandro Russo, Marco Russano, Tindara Franchina, Maria R Migliorino, Giuseppe Aprile

Adv Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Francesco Pantano, Marco Russano, Alfredo Berruti, Giovanni Mansueto, Maria R Migliorino

Expert Opin Biol Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Alessio Cortellini, Melissa Bersanelli, Daniele Santini, Sebastiano Buti, Marcello Tiseo, Maria Rita Migliorino

Eur J Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis